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Research Highlights:  
 Results suggest the activity monitors are less accurate in PMR than healthy people 
 Fitbit-Zip appears to fairly accurately measure step-count during walking in PMR 
 Results suggest Actigraph with LFE was the most accurate device for stair ascent 
 Device accuracy decreased in PMR patients with higher functional impairment  
 Actigraph’s LFE filter increased device accuracy in controlled conditions 
 
 
Abstract 
Background  
Activity monitors provide objective measurements of physical activity, however, the accuracy 
of these devices in people with polymyalgia rheumatica (PMR) is unknown. Therefore, this 
study aimed to obtain preliminary evidence of the accuracy of two activity monitors and 
explore if clinical and gait-related factors altered device accuracy in people with PMR. 
Methods 
The ActiGraph with low frequency extension (+LFE) and standard (-LFE) algorithms, Fitbit-
Zip (waist) and Fitbit-Zip (shirt) were concurrently tested using a two-minute walk test 
(2MWT) and stairs test in 27 people with PMR currently treated with prednisolone. To 
determine accuracy, activity monitor step-count was compared to a gold-standard step-count 
(GSSC; calculated from video recording) using Bland-Altman plots.  
 Results 
The Fitbit-Zip (waist) achieved closest agreement to the GSSC for the 2MWT (mean bias 
(95%CI): 10 (-3, 23); 95%LOA: -55, 74). The ActiGraph (+LFE) achieved closest agreement 
to the GSSC for the stairs test (mean bias (95%CI): 0 (-1, 1); 95%LOA: -5, 5). The ActiGraph 
(-LFE) performed poorly in both tests. All devices demonstrated reduced accuracy in 
participants with lower gait velocity, reduced stride length, longer double-limb support phase 
and greater self-reported functional impairment. 
Conclusion 
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Our preliminary results suggest that in controlled conditions, the Fitbit-Zip fairly accurately 
measures step-count during walking in people with PMR receiving treatment. However, 
device error was greater than data published in healthy people. The ActiGraph may not be 
recommended without activation of the LFE. We identified clinical and gait-related factors 
associated with higher levels of functional impairment that reduced device accuracy. Further 
work is required to evaluate the validity of the activity monitors in field conditions. 
 
Key words: Activity monitoring, Physical activity, Step-count, Polymyalgia rheumatica, 
Accelerometers, Device comparison  
 
1. Introduction 
Promoting physical activity is a key aspect of public health policy [1], and advice on 
increasing physical activity is commonly given during clinical consultations. Despite this, an 
estimated one third of adults globally do not meet recommended exercise guidelines; 
inactivity is even higher in older adults and people with chronic disease [1]. Polymyalgia 
rheumatica (PMR) is a common chronic, inflammatory musculoskeletal disease that usually 
affects adults over the age of 50 [2, 3]. PMR is treated with systemic glucocorticoid therapy, 
which often causes proximal myopathy and weight gain, exacerbating the effect of pre-
existing osteoarthritis on gait, posture and mobility [4]. Physical activity and exercise are 
therefore recommended to mitigate physical deconditioning and promote bone health [5].   
Wearable accelerometers that measure step-count are popular devices for self-tracking 
physical activity and are a useful self-management support tool for increasing physical 
activity in daily life [6]. The ability of the user to create goals and track step-counts in real 
time is thought to positively change exercise behaviour [7], which might be useful for people 
with PMR. Popular consumer activity monitors such as the Fitbit-Zip and research 
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accelerometers such as the ActiGraph, can accurately measure step-count in healthy young [8-
11] and older [12] adults. A Low Frequency Extension (LFE) filter was developed for the 
ActiGraph to increase sensitivity and improve step-count accuracy during lower-intensity 
movements. However, the algorithms used to calculate step-count were developed on young, 
healthy people. Many clinical conditions are associated with abnormalities of gait and posture 
that have been shown to affect the accuracy of these algorithms [12-17], yet step-count 
accuracy has not been tested in people with PMR. Prior to using activity monitors to measure 
the physical activity of this population and developing subsequent interventions to increase 
physical activity, it is important to explore the validity of activity monitors in this target 
population. 
Movement type and direction also affect the accuracy of activity monitors to record 
steps [18]. However, step-count accuracy has most commonly been assessed during rhythmic 
movement with forward motion, such as walking or running. Walking up stairs is a common 
activity which involves different movement patterns to walking on a flat surface but has rarely 
been explored in studies measuring step-count accuracy [8]. Furthermore, the effect of 
ActiGraph’s LFE filter on step-count accuracy has not been tested during stair climbing. 
The purpose of this study was to obtain preliminary evidence of the accuracy of two 
commonly used activity monitors in patients with PMR who are treated with systemic 
glucocorticoid therapy. The performance of the Fitbit-Zip and ActiGraph devices were 
compared to direct measurement using video-observation, in a group of patients on 
glucocorticoid treatment for PMR. Device accuracy was assessed during walking on flat 
ground and ascending stairs, as examples of everyday activities with different movement 
patterns. The effect of Fitbit-Zip monitor location (chest vs. waist) and the application of the 
ActiGraph LFE filter on step-count accuracy was also explored. Lastly, in exploratory 
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analyses we examined associations between gait-related and clinical variables and device 
error. 
2. Methods 
2.1. Participants  
Patients were recruited from rheumatology outpatient clinics between 2015 and 2016. 
All patients had a consultant-confirmed diagnosis of PMR according to clinical practice 
guidelines [19], were treated with systemic glucocorticoids (prednisolone) for at least one 
month, and agreed to walk for at least two minutes. The Leeds NHS Research Ethics 
Committee granted ethical approval (Ref:14/YH/1147) and all patients provided written 
consent prior to participation in accordance with the Declaration of Helsinki. 
2.2. Activity Monitors  
The Fitbit-Zip (Fitbit, Inc, San Francisco, USA) is a small, commercially-available 
physical activity monitor worn at the waist or midline of the shirt. Step-counts are displayed 
on the LCD screen. The ActiGraph-GT3X+ (ActiGraph LLC, Pensacola, USA) is a slightly 
larger research device most commonly worn at the hip. Raw data are downloaded and 
processed using ActiLife.6 software on a computer, generating output parameters including 
step-count.  Both devices use the integrated 3-axis accelerometer, which quantifies 
acceleration, to calculate step-counts using manufacturers’ algorithms. Individual gait 
parameters such as stride length are not considered in these algorithms. 
2.3. Study Protocol  
On the assessment day, participants’ height and weight were measured and 
participants completed patient-reported outcome questionnaires; the Stanford Health 
Assessment Questionnaire Disability Index (HAQ-DI) [20] and the Functional Assessment of 
Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire [21]. Gait velocity, stride 
length and duration of double-limb support phase (DLSP) were measured while the 
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participants walked at a self-selected normal pace, using the previously validated GAITRite 
walkway [22]. Participants’ leg length was measured and entered into the GAITRite software 
(CIR Systems Inc., Sparta, USA) to enable the calculation of the gait parameters, as per the 
manufacturer’s instructions. Serum C-reactive protein (CRP) was measured within one week 
of the study visit, as part of the clinical assessment for PMR disease activity.  
Participants completed a two-minute-walk-test (2MWT) and stairs test whilst 
simultaneously wearing three devices (one ActiGraph and two Fitbit-Zip monitors). The 
ActiGraph and first Fitbit-Zip were mounted side-by-side on participants’ right hip using an 
elastic waistband, whilst the second Fitbit-Zip was attached to the midline of the shirt. 
Throughout the tests, participants were asked to walk at their normal pace and use any 
assistive devices required. Participants were allowed to rest or stop the test where necessary. 
To avoid recording extra steps, participants were asked to remain still at the end of each test 
whilst step-count data were transcribed from the devices.  
 The 2MWT evaluated step-count accuracy of devices whilst freely walking on flat 
ground. Participants walked around the gait laboratory, using a self-dictated route for a total 
of two minutes. 
 The stairs test evaluated step-count accuracy of devices during stair ascent. 
Participants were seated at the bottom of a 12-step staircase in the hospital, and asked to 
ascend the stairs and sit down on a chair placed at the top of the staircase. Throughout both 
tests, video footage was recorded to accurately capture steps and enable later calculation of 
the gold standard step-count (GSSC). Different ActiGraph devices were used for each test for 
practicality reasons, as tests were performed sequentially and the staircase was not adjacent to 
the gait laboratory.  
2.4 Data processing and analysis 
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In the absence of existing data on which to base a power calculation the sample size 
was based on published rules of thumb for preliminary studies, which recommend up to 30 
patients be recruited [23]. This is comparable to previous validation studies that have used 
sample sizes between 21 to 32 [9, 12, 15, 24]. Fitbit-Zip step-count was calculated as the 
difference between steps displayed on the device at the start and end of each test. The 
ActiGraph devices recorded step-counts at 30Hz for two minutes during the 2MWT and one 
minute for the stairs test. Step-count data were analysed in 60-second epochs, with and 
without the LFE filter, using ActiLife software (v.6.13.2, ActiGraph LLC). The LFE aims to 
improve step-count accuracy by changing the band-pass filter settings to enable low-intensity 
activities to be recorded. Preliminary evidence of step-count accuracy was obtained for four 
device conditions: Fitbit-Zip (waist), Fitbit-Zip (shirt), ActiGraph (-LFE) and ActiGraph 
(+LFE).  
 To calculate the GSSC of each test, two researchers (A.C and E.H) replayed videos of 
each participant at half-speed, and individually counted the number of steps three times whilst 
blinded to the other’s count, to yield a mean value. A step was defined as a ‘transition from 
the first point of contact of one foot with the ground, through to the first point of contact with 
a contralateral foot’. As such, participants’ feet did not need to completely leave the ground to 
be counted as a step, in order to account for shuffling. Inter- and intra-rater reliability (IRR) of 
visual count from video-recordings were assessed concurrently using fixed-effects intra-class 
correlation coefficient (ICC), calculated according to Eliasziw et al [25]. An ICC<0.20 was 
considered slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 substantial and 0.81-1.00 
almost perfect [25].  
Bland-Altman plots measured agreement between activity monitors and the GSSC 
[26, 27]. Plots described accuracy of each device by the mean step-count difference (bias) and 
95% limits of agreement (95%LOA). The more narrow the 95%LOA and closer the bias to 
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the line of equality (Y=0), the more accurate the device, and vice versa. As recommended by 
Bland et al [27], outliers were not excluded during analysis. If the difference between 
measurements was found to be related to the mean measurement, the regression method was 
used to calculate the 95%LOA. If the absolute values of the residuals from the regression 
model were found to be related to the mean measurement at p<.05, the 95%LOA were 
adjusted accordingly [27]. Mean absolute percentage error (MAPE) was also calculated. 
 For consistency non-parametric Spearman’s rank correlation was used to assess all 
associations between step-count bias and demographic, clinical and gait parameters because 
many of the interval-scaled outcomes were highly skewed (Body Mass Index (BMI), steroid 
dose, CRP, stride length, gait velocity) and the patient-reported outcomes (HAQ-DI, FACIT-
Fatigue) were ordinal-scaled. Absolute rho values ≥0.3 were considered substantive. All 
analyses were performed using Stata software (Stata v.14.1, StataCorp, College Station, TX, 
USA). 
4.  Results 
4.1  Participant Characteristics and associations between gait-related and clinical 
variables 
Demographic and clinical characteristics of the 27 patients who took part in the study 
are presented in Table 1. Three patients also had giant cell arteritis (GCA) and two had a 
diagnosis of osteoarthritis (OA). One patient used two walking canes during both tests and 
nine used the handrail during stair-ascent. Age, HAQ-DI scores and CRP were found to have 
substantive and statistically significant (rho>0.4, p < 0.05) associations with DLSP, stride 
length and gait velocity. In addition, DLSP demonstrated association to the same degree with 
BMI. Several other associations (0.40>rho>0.30) were also found (Table 2).  
4.2  Step-count accuracy 
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All participants except one completed both tests; due to fatigue this participant was 
only able to complete 30s of the 2MWT and was unable to complete the stairs test. This 
participant’s 2MWT data was included in analysis as recommended by Bland et al., [27]. 
Step-count data is detailed in the supplementary file (supplementary Table 1). For the gold-
standard video assessment, IRR between observers was almost perfect for both tests 
(ICC>0.99). All monitors systematically underestimated step-counts during the 2MWT and 
stairs test, as demonstrated by the mean bias falling above the line of equality (Y=0; Figures 1 
and 2). During the 2MWT, the Fitbit-Zip (waist) achieved the closest agreement to the GSSC, 
followed by the Fitbit-Zip (shirt), ActiGraph (+LFE) and ActiGraph (-LFE) (Figure 1, Table 
3). Conversely, during the stairs test, the ActiGraph (+LFE) achieved the closest agreement to 
the GSSC, followed by the Fitbit-Zip (waist) and ActiGraph (-LFE), whilst the Fitbit-Zip 
(shirt) attained the poorest agreement (Figure 2, Table 3).  
Although the Fitbit-zip (shirt) performed well during the 2MWT, it was less accurate 
during the stairs test. This was largely due to two anomalous results where the Fitbit-zip 
(shirt) recorded 207 steps and zero steps on two different occasions. It is unclear whether this 
was device or human error. Sensitivity analysis excluding these two results improved the 
step-count accuracy of the Fitbit-zip (shirt) from 64% mean error to 10% mean error 
(supplementary Table 2). Apart from these two anomalous results, the position of the Fitbit 
had little effect on step-count accuracy. 
 ActiGraph’s LFE algorithm had a large effect on device accuracy; the default setting 
(-LFE) reduced device accuracy during both tests and increased step-count underestimation 
when fewer steps were taken (higher mean bias and wider 95%LOA, Table 3). When LFE 
was activated, step-count agreement was improved and more comparable to the Fitbit-zip 
(Table 3), although mean step-count bias was still larger than the Fitbit-zip for the 2MWT.  
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 Bland-Altman plots (Figure 1) demonstrated that participants who took fewer steps 
during the 2MWT recorded greater step-count underestimation in all devices, especially the 
ActiGraph (-LFE). For all devices, step-count bias correlated negatively with gait velocity 
(rho=-.37 to -.58) and stride length (rho=-.31 to -.72) and positively with HAQ-DI scores 
(rho=.32 to .57) and duration of DLSP (rho=.33 to .61; Table 2).  
5. Discussion 
This study was the first to measure the accuracy of accelerometer-based activity 
monitors in people with PMR. Based on close agreement with the video-recorded gold-
standard, our preliminary results suggest that the Fitbit-Zip (waist) was the most accurate 
measure of step-count whilst walking on flat ground in people with PMR, closely followed by 
the Fitbit-Zip (shirt). In contrast, the ActiGraph (+LFE) was the most accurate device during 
stair ascent, followed by the Fitbit-Zip (waist) then ActiGraph (-LFE). The Fitbit-Zip (shirt) 
was the poorest performing when all participants were included. However, when two 
anomalous results were excluded, its accuracy was similar to the Fitbit-Zip (waist) and 
ActiGraph (+LFE). Altered lower limb kinematics may explain the differences in step-count 
accuracy between level walking and stair climbing; larger knee and hip flexion and no heel 
contact with the ground are observed during stair ascent. This may have resulted in larger 
acceleration, which devices are more able to detect. [28]. The ActiGraph (-LFE) was more 
accurate than Fitbit-Zip (shirt) on the stairs test when all patients were included; however, 
when two anomalous results were excluded, it had the greatest mean bias and widest limits of 
agreement of all tests. 
Consistent with previous findings in older adults [12], our results also suggest the 
Fitbit-Zip to be more accurate than ActiGraph for recording step-count during level walking. 
Although the FitBit-zip (waist) performed better than the other device conditions, it still 
performed relatively poorly in PMR patients (Table 3), compared to published data from 
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healthy young adults [8]. Similarly, while the ActiGraph (+LFE) performed best during stair 
ascent, the step-count mean error was considered large at 8%.  
Step-count accuracy was lower in participants who took fewer steps during the 
2MWT, walked slower, had shorter stride length, longer double-limb support phase and 
greater self-reported functional impairment. Previous studies have reported similar findings in 
older adults [12, 14] although in one young, healthy population, walking speed did not affect 
step-count accuracy [8]. This was likely because the population studied did not have gait 
abnormalities and the lowest speed tested was 90 cm/s [8]. Indeed, FitBit-zip (waist) step-
count accuracy is reported to be as high as 98% at walking speeds of 90 cm/s but as low as 
47% at 50 cm/s [13].   
Step-count error at slower walking speeds in PMR might be explained by device 
algorithms that convert raw acceleration profiles into step-counts, or inaccuracies in device 
hardware itself [29]. Accelerations during movement must meet/surpass a threshold in order 
for a step to be recognised. However, the algorithms were based on kinetic gait characteristics 
of healthy adults [30]. At slower walking speeds, the acceleration amplitude is lower [31], and 
may be insufficient to surpass the acceleration threshold required to register a valid step [32]. 
This mechanism may explain why step-count error was exacerbated in ActiGraph devices 
without activation of LFE during level walking and stair climbing.  
ActiGraph’s LFE filter reduces the acceleration threshold by expanding the bandwidth 
of the normal software filtering algorithm [33]. This increases the lower limit of the 
acceleration cut-off, which increases ActiGraph’s sensitivity to low-intensity movements that 
was observed in participants this study; (the median gait velocity was slower than published 
data on age-matched healthy people [34]). During both tests in this study, the Actigraph’s 
step-count accuracy was improved by activating LFE. Although this is consistent with 
previous studies conducted in controlled conditions [33, 35], the activation of LFE in free-
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living conditions in young and older adults overestimates step-count [33, 36]. Therefore, 
further research is required to evaluate the validity of these activity monitors in PMR in free-
living conditions.  
5.1 Strengths and Limitations: 
This study tested two commonly used activity monitors in a well-defined clinical 
cohort of PMR patients, using a protocol previously described in similar studies [12, 15]. 
Error attributable to intra-subject variation was minimised because the devices were tested 
concurrently. The controlled laboratory environment of our study facilitated a fair, repeatable 
objective evaluation of activity monitors. Although the study evaluated the activity monitors 
in both walking along a flat surface and on stairs, the controlled conditions may limit external 
validity. Therefore, it is important that the activity monitors are further tested in free-living 
conditions outside of the laboratory environment.  
Bland-Altman plots enabled separation of systematic error from the activity monitor 
and random error from unknown/unpredictable changes in the experiment [37], such as 
human error. It is therefore an appropriate method for testing agreement and thus, 
interchangeability between two methods of measuring step-count (i.e. GSSC vs. activity 
monitor) [27]. Validation studies such as this may benefit from implementing a priori criteria 
that states the minimal clinically important difference in step-count between accelerometer 
and GSSC, based on the clinical and biological traits of people with PMR. In theory this 
would further optimise the Bland-Altman system [26] and thus statistical validity. 
Furthermore, we have explored clinical factors influencing accuracy that might introduce 
systematic bias into analyses of clinical studies in which physical activity is incorporated as 
either a covariate or an outcome. Due to the small sample size in this study, our results are 
preliminary and should be confirmed in a further study with a larger sample size. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
13 
 
Females are more likely to develop PMR than males [3], which is reflective of the 
gender distribution in this study. Gender based differences in gait patterns have been 
previously reported [38, 39]. Although this could potentially affect the accuracy of activity 
monitors, exploring this possibility was beyond the scope of this study. 
6.0 Conclusion:  
Our preliminary results suggest that in controlled conditions, the Fitbit-Zip is a fairly 
accurate measure of step-count during walking in people with PMR receiving glucocorticoid 
treatment. However, when compared to validation data published in healthy people, the 
devices were not as accurate for measuring steps. Further research is needed to determine its 
accuracy during stair ascent when worn on the chest. Step-count accuracy of ActiGraph 
devices appears to be improved with activation of the LFE filter. Increasing functional 
impairment or gait abnormalities reduced step-count accuracy in all devices. Further work is 
required to evaluate the validity of these activity monitors in field conditions.  
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Figure Captions 
 
Figure 1. Bland-Altman plots measuring and comparing step-count agreement between 
activity monitors and the gold-standard during the Two-Minute-Walk-Test (2MWT). The 
more narrow the 95% limits of agreement and closer the bias is to the line of equality, Y=0 
(i.e. perfect average agreement) the closer the device agrees to the gold standard step-count 
(i.e. the more accurate) and vice versa. Fitbit-Zip (waist) achieved closest agreement (Figure 
1a). All participants completed the 2MWT (n=27).  
 
Figure 2. Bland-Altman plots measuring and comparing step-count agreement between 
activity monitors and the gold-standard during the Stairs Test. The more narrow the 95% 
limits of agreement and closer the bias is to the line of equality, Y=0 (i.e. perfect average 
agreement) the closer the device agrees to the gold-standard step-count (i.e. the more 
accurate) and vice versa. Actigraph (+LFE) achieved closest agreement (Figure 2d), followed 
closely by Fitbit-Zip (waist) (Figure 2a). Twenty six participants completed the stairs test.  
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Table Captions 
 
Table 1.   
Summary statistics for patient demographics and clinical details.  
Key: %GC = percentage of gait cycle, SD = Standard deviation, IQR = Inter-quartile range, BMI = Body Mass Index, CRP = C-Reactive 
Protein, HAQ-DI = Stanford Health Assessment Questionnaire Disability Index, FACIT-Fatigue = Functional Assessment of Chronic Illness 
Therapy-Fatigue. The maximum possible HAQ-DI score is 3; higher HAQ-DI scores indicate higher functional impairment. The maximum 
possible FACIT-Fatigue score is 52; higher FACIT-Fatigue scores indicate lower levels of fatigue. Double support refers to the proportion of 
the gait cycle spent in double-limb support (DLS), measured as a percentage of the gait cycle. For a normal gait cycle, DLS is approximately 
20%. People with mobility issues usually have higher values for DLS. 
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Key: %GC = percentage of gait cycle, SD = Standard deviation, IQR = Inter-quartile range, BMI = Body Mass Index, CRP = C-Reactive 
Protein, HAQ-DI = Stanford Health Assessment Questionnaire Disability Index, FACIT-Fatigue = Functional Assessment of Chronic Illness 
Therapy-Fatigue. The maximum possible HAQ-DI score is 3; higher HAQ-DI scores indicate higher functional impairment. The maximum 
possible FACIT-Fatigue score is 52; higher FACIT-Fatigue scores indicate lower levels of fatigue. Double support refers to the proportion of 
the gait cycle spent in double-limb support (DLS), measured as a percentage of the gait cycle. For a normal gait cycle, DLS is approximately 
20%. People with mobility issues usually have higher values for DLS.  
 
  
 Median (IQR) Mean (SD) Range 
Number of 
participants 
(%) 
Female  -  -  -  24 (89) 
Age (years) -  69.2 (8.8) 50 - 85 27 (100) 
BMI (kg/m2) -  28.3 (5.6) 19.9 – 40.4 27 (100) 
Gait Velocity (cm/s)  119 (95, 131)  - 46 – 142  27 (100) 
Stride length (cm) 125 (111, 140) - 61 – 163 27 (100) 
Double Support (%GC) 25.9 (23.9, 29.8) -  20.4 – 38.0 27 (100) 
Daily steroid dose (mg) 9.0 (5.0, 12.5) - 1 – 40 27 (100) 
CRP (mg/L) <5 (<5, 17) - <5 – 60  25 (92.6)  
HAQ-DI  0.63 (0.13, 1.25) - 0.00 – 2.13 26 (96.3) 
FACIT-Fatigue 38 (33, 45) - 5 – 51  25 (92.6)  
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Table 2. Spearman’s rho associations of factors influencing gait and step-count bias 
 
The first section of this table shows the associations between gait parameters and demographic and clinical parameters whilst the second section shows associations between step-count bias and demographic, clinical 
and gait parameters. |Rho| ≥0.3 is considered to be substantive association (for reference, threshold rho values for statistical significance in this sample size are ≥ 0.4 p < 0.05; ≥-0.33 p < 0.1). Values highlighted in bold 
indicate correlations where substantive association was found. 
Key: BMI = Body Mass Index, CRP = C-Reactive Protein, HAQ-DI = Stanford Health Assessment Questionnaire Disability Index, FACIT-Fatigue = Functional Assessment of Chronic Illness Therapy-Fatigue. 
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The first section of this table shows the associations between gait parameters and demographic and clinical parameters whilst the second section shows associations between step-count bias and demographic, clinical 
and gait parameters. |Rho| ≥0.3 is considered to be substantive association (for reference, threshold rho values for statistical significance in this sample size are ≥ 0.4 p < 0.05; ≥-0.33 p < 0.1). Values highlighted in bold 
indicate correlations where substantive association was found. 
Key: BMI = Body Mass Index, CRP = C-Reactive Protein, HAQ-DI = Stanford Health Assessment Questionnaire Disability Index, FACIT-Fatigue = Functional Assessment of Chronic Illness Therapy-Fatigue. 
 
  
 Gait parameters Two minute walk test (n = 27) 
      step-count bias 
Stairs test (n = 26) 
                step-count bias 
 Stride 
length 
Gait 
velocity 
Duration double 
support phase 
Fitbit-zip Actigraph Fitbit-zip Actigraph 
 Waist Shirt -LFE +LFE Waist Shirt -LFE +LFE 
Age -0.47 -0.45 0.44 .46 .58 .34 .37 -.04 .10 -.16 -.09 
BMI -0.37 -0.30 0.56 .02 -.08 .26 .01 .04 .02 .20 .03 
Steroid dose -0.23 -0.22 0.35 .24 .20 .23 .43 .06 .24 -.07 -.16 
CRP -0.48 -0.45 0.45 .25 .33 .22 .07 .15 .12 .12 .16 
HAQ-DI -0.65 -0.57 0.62 .55 .46 .57 .35 .32 .40 .50 .41 
FACIT-Fatigue 0.37 0.30 -0.25 -.33 -.08 -.55 -.23 -.28 -.23 -.38 -.43 
Stride length    -.55 -.47 -.72 -.45 -.50 -.45 -.34 -.31 
Gait velocity    -.43 -.44 -.56 -.37 -.58 -.46 -.42 -.40 
Duration of 
double support 
   
.49 .44 .61 .43 .40 .33 .39 .37 
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Table 3. Bland-Altman 95% limits of agreement, bias (mean difference) and mean absolute percentage error for Two Minute Walk Test and Stair 
test. 
The table illustrates the key statistics taken from Bland-Altman analysis. Bias indicates the mean difference between the gold standard step-count and device, whilst the 95%LOA demonstrates the upper and lower 
limits of agreement. The smaller the 95%LOA and closer the bias to the point of equality (Y=0), the more accurate the activity monitor is.    
*Due to association between bias and magnitude of measurement, the Bland-Altman regression method was used to determine mean bias as a function of the mean count [(test count + gold standard count)/2]. 
Key: 95% LOA = 95% Limits of Agreement, MAPE = Mean absolute percentage error, LFE = Low frequency extension algorithm. 
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The table illustrates the key statistics taken from Bland-Altman analysis. Bias indicates the mean difference between the gold standard step-count and device, whilst the 95%LOA demonstrates the upper and lower limits 
of agreement. The smaller the 95%LOA and closer the bias to the point of equality (Y=0), the more accurate the activity monitor is.    
*Due to association between bias and magnitude of measurement, the Bland-Altman regression method was used to determine mean bias as a function of the mean count [(test count + gold standard count)/2] 
Key: 95% LOA = 95% Limits of Agreement, LFE = Low frequency extension algorithm, MAPE = Mean absolute percentage error, SD=standard deviation. 
 
Activity Monitor  
   
Two minute walk test (n=27) Stairs (n=26) 
Mean bias (95%CI) 95% LOA MAPE % (SD) Bias (95% LOA) 95% LOA MAPE % (SD) 
Fitbit-zip (waist)  10 (-3, 23) -55, 74 6 (17) 1 (-1, 3) -8, 10 12 (20) 
Fitbit-zip (shirt)  12 (-2, 27) -58, 83 6 (19) -6 (-22, 9) -81, 68 64 (258) 
Actigraph (-LFE)  
141+(-0.5*mean 
count)* 
110+(-0.5*mean 
count)* 
30 (22) 4 (2, 6) -4, 12 22 (16) 
Actigraph (+LFE)  20 (8, 33) -40, 81 10 (16) 0 (-1, 1) -5, 5 8 (9) 
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